NO20043749L - Stabilt farmasoytisk preparat omfattende torsemidmodifikasjon II - Google Patents
Stabilt farmasoytisk preparat omfattende torsemidmodifikasjon IIInfo
- Publication number
- NO20043749L NO20043749L NO20043749A NO20043749A NO20043749L NO 20043749 L NO20043749 L NO 20043749L NO 20043749 A NO20043749 A NO 20043749A NO 20043749 A NO20043749 A NO 20043749A NO 20043749 L NO20043749 L NO 20043749L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical preparation
- stable pharmaceutical
- torsemide modification
- torsemide
- modification
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229960005461 torasemide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/071,423 US20030022921A1 (en) | 2001-02-21 | 2002-02-08 | Stable pharmaceutical formulation comprising torsemide modification II |
| PCT/US2003/003701 WO2003066023A1 (en) | 2002-02-08 | 2003-02-07 | A stable pharmaceutical formulation comprising torsemide modification ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043749L true NO20043749L (no) | 2004-09-07 |
Family
ID=27732277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043749A NO20043749L (no) | 2002-02-08 | 2004-09-07 | Stabilt farmasoytisk preparat omfattende torsemidmodifikasjon II |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030022921A1 (is) |
| EP (1) | EP1359900A4 (is) |
| JP (1) | JP2005518422A (is) |
| KR (1) | KR20040081183A (is) |
| CN (1) | CN1646094A (is) |
| AU (1) | AU2003210903A1 (is) |
| CA (1) | CA2455881A1 (is) |
| DE (1) | DE03702168T1 (is) |
| ES (1) | ES2209686T1 (is) |
| HR (1) | HRP20040757A2 (is) |
| IS (1) | IS7384A (is) |
| MX (1) | MXPA04007695A (is) |
| NO (1) | NO20043749L (is) |
| PL (1) | PL372221A1 (is) |
| WO (1) | WO2003066023A1 (is) |
| ZA (1) | ZA200406026B (is) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1811957T1 (sl) * | 2004-10-19 | 2009-04-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Trden farmacevtski sestavek, ki obsega donepezil hidroklorid |
| CN114641278A (zh) * | 2019-09-11 | 2022-06-17 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶抑制剂的药物配制品 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
| JP4105762B2 (ja) * | 1995-02-28 | 2008-06-25 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ピペリジノアルカノール化合物のための医薬組成物 |
| US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
| PL354262A1 (en) * | 1999-08-11 | 2003-12-29 | Teva Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd. | Torsemide polymorphs |
| SK11632003A3 (sk) * | 2000-02-17 | 2004-04-06 | Teva Pharmaceutical Industries Ltd. | Stabilný farmaceutický prípravok obsahujúci modifikáciu II torsemidu |
| US20030119882A1 (en) * | 2001-10-22 | 2003-06-26 | Markus Maegerlein | Solid pharmaceutical composition containing torasemide |
-
2002
- 2002-02-08 US US10/071,423 patent/US20030022921A1/en not_active Abandoned
-
2003
- 2003-02-07 HR HRP20040757 patent/HRP20040757A2/xx not_active Application Discontinuation
- 2003-02-07 WO PCT/US2003/003701 patent/WO2003066023A1/en not_active Ceased
- 2003-02-07 CN CNA038078260A patent/CN1646094A/zh active Pending
- 2003-02-07 AU AU2003210903A patent/AU2003210903A1/en not_active Abandoned
- 2003-02-07 DE DE0001359900T patent/DE03702168T1/de active Pending
- 2003-02-07 KR KR10-2004-7012088A patent/KR20040081183A/ko not_active Ceased
- 2003-02-07 MX MXPA04007695A patent/MXPA04007695A/es not_active Application Discontinuation
- 2003-02-07 PL PL03372221A patent/PL372221A1/xx not_active Application Discontinuation
- 2003-02-07 ES ES03702168T patent/ES2209686T1/es active Pending
- 2003-02-07 CA CA002455881A patent/CA2455881A1/en not_active Abandoned
- 2003-02-07 JP JP2003565448A patent/JP2005518422A/ja not_active Withdrawn
- 2003-02-07 EP EP03702168A patent/EP1359900A4/en not_active Withdrawn
-
2004
- 2004-07-28 ZA ZA200406026A patent/ZA200406026B/en unknown
- 2004-08-05 IS IS7384A patent/IS7384A/is unknown
- 2004-09-07 NO NO20043749A patent/NO20043749L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1359900A4 (en) | 2004-05-19 |
| EP1359900A1 (en) | 2003-11-12 |
| KR20040081183A (ko) | 2004-09-20 |
| HRP20040757A2 (en) | 2004-12-31 |
| PL372221A1 (en) | 2005-07-11 |
| JP2005518422A (ja) | 2005-06-23 |
| WO2003066023A9 (en) | 2003-11-20 |
| DE03702168T1 (de) | 2004-07-08 |
| AU2003210903A1 (en) | 2003-09-02 |
| US20030022921A1 (en) | 2003-01-30 |
| CA2455881A1 (en) | 2003-08-14 |
| ZA200406026B (en) | 2006-07-26 |
| WO2003066023A1 (en) | 2003-08-14 |
| IS7384A (is) | 2004-08-05 |
| CN1646094A (zh) | 2005-07-27 |
| MXPA04007695A (es) | 2004-12-07 |
| ES2209686T1 (es) | 2004-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20033143L (no) | Farmasoytisk preparat | |
| NO20030418L (no) | Nytt farmasöytisk preparat | |
| PT1501534E (pt) | Formulacoes farmaceuticas | |
| KR20050009999A (ko) | 약제학적 제제 | |
| NO20033556L (no) | Farmasöytiske formuleringer | |
| ATE380544T1 (de) | Umhüllte feste darreichungsform | |
| IS7298A (is) | Platínuafleiða lyfjasamsetningar | |
| NO20034026D0 (no) | Nytt preparat | |
| DE602004017700D1 (de) | Transmukosen verabreichung | |
| EE200300416A (et) | Ravimvorm | |
| NO20033042L (no) | Cyklodekstrin-inneholdende farmasöytisk preparat | |
| NO20035627D0 (no) | Farmasöytisk formulering | |
| NO20052239D0 (no) | Fast preparat | |
| NO20015149D0 (no) | Nytt farmasöytisk preparat | |
| NO20025805D0 (no) | Farmasöytisk preparat | |
| NO20034695L (no) | Nytt preparat | |
| NO20015148D0 (no) | Nytt farmasöytisk preparat | |
| NO20015104L (no) | Nytt farmasöytisk preparat | |
| NO20015105L (no) | Nytt farmasöytisk preparat | |
| NO20060375L (no) | Famasoytisk preparat | |
| NO20043749L (no) | Stabilt farmasoytisk preparat omfattende torsemidmodifikasjon II | |
| NO20021036D0 (no) | Farmasöytisk preparat | |
| NO20041236L (no) | Farmasoytisk formulering | |
| SE0201660D0 (sv) | Pharmaceutical formulation | |
| SE0200449D0 (sv) | Pharmaceutical formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |